Read about a new study that suggests a person’s risk of progressing from a benign condition called monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma can change over time.
Scientists have discovered an immune checkpoint protein that may be a new target for immunotherapy. Learn about this protein and the types of cancers that might be targeted by blocking it.
An NCI-funded clinical trial is testing the immunotherapy drug nivolumab (Opdivo) in people who have advanced cancer and an autoimmune disease, such as rheumatoid arthritis, lupus, or multiple sclerosis, who are often excluded from such trials.
Review this updated page to learn about sentinel lymph node biopsy, including why it is used, when it is used, and the benefits and harms of the procedure.
In this new PDQ summary, learn who might benefit from genetic counseling and testing for kidney cancer and about the four known hereditary kidney cancer syndromes and the genes that cause them. It also has new medical drawings to explain autosomal inheritance and show areas of the body affected by the different syndromes.
We’ve added a new drug information summary on darolutamide (Nubeqa), which was recently approved by the Food and Drug Administration to treat metastatic prostate cancer that is castration resistant.
When Valerie Winston was diagnosed with smoldering myeloma, she was not comfortable with the standard watch-and-wait approach and decided to join a clinical trial. Read more about her story.
This page explains how to use the basic and advanced clinical trials search forms to find NCI-supported clinical trials, how to understand the trials that you find, and ways to get more help.
